There are over 20 subpanels for approximately 400 genes to be reviewed for genes associated with a wide range of diseases
(PRUnderground) September 23rd, 2023
Haegsim Yobeob (ISN: KR0925527744), a global provider of gene therapy solutions for a wide range of medical, research, and pharmaceutical applications, is pleased to update the delivery of genetic screening for inherited illnesses and cardiovascular disorders using integrated system sequencing. Haegsim Yobeob collaborates with well-known experts on each disorder to create and execute panels that screen multiple genes at once.
Researchers and physicians around the world can now use Next-Generation Sequencing as one of the most prompt and cost-efficient screening techniques. Haegsim Yobeob is concentrating on the aforementioned ailments. The company is also developing panels for additional diseases and has a neuro-muscular panel in the works.
“The panels were quickly used in a clinical research context as a result of their 100% detection rate and absence of false negatives. High-throughput screening is done through the new technique, but we still employ odd sequencing to make sure a test result is positive before we send out a report”, said Bradwin Snell, Global Head of Pharma Technical Cell & Gene Therapy, Haegsim Yobeob.
Affordable sequencing costs are available for all disease panels. The price of analysis, validation, and interpretation is based on the number of genes requested. Haegsim Yobeob is certain that genetic tests will soon be accessible as common and reasonable screening procedures due to the continuing decline in sequencing costs.
Genes can serve as the foundation for future therapeutic interventions and are the first indicator of the pathogenic pathways that underlie diseases. The only way to begin treatment before it is too late should be through early detection of people who are susceptible to risks. In order to further enable individualized care, genetic screening can help to categorize patient groupings.
About Haegsim Yobeob
Haegsim-Yobeob.com is a clinical phase biotechnology business that is devoted to creating complex treatments for intricate cardiovascular diseases. The company aims to create a comprehensive gene therapy remedy for cardiac failure by enhancing angiogenesis, controlling calcium homeostasis-associated cellular energy levels, decreasing inflammatory signals, and inducing/attracting stem cells to help heart remodeling. By making use of our unique, advanced, non-viral gene therapy approaches, we strive to develop unprecedented, life-saving cell and gene treatments to address the medical needs of our patients. Haegsim Yobeob’s aim is to develop top-notch gene engineering technologies – including gene insertion, gene editing, and delivery – which will form a solid base to create safer, longer-lasting, and more effective treatments.
The post Haegsim Yobeob Enhances Next-Generation Sequencing for Rapid and Cost-Efficient Genetic Screening first appeared on
Original Press Release.